齐拉西酮与喹硫平治疗早期精神分裂症的对照研究  

Comparative study of ziprasidone and quetiapine in the treatment of early schizophrenia

作　　者：薛冬丽[1] 倪晓梅[1] 

机构地区：[1]沈阳市精神卫生中心,110168

出　　处：《中国现代药物应用》2015年第4期1-2,共2页Chinese Journal of Modern Drug Application

摘　　要：目的比较齐拉西酮与喹硫平治疗早期精神分裂症的疗效及不良反应。方法 100例精神分裂症患者随机分为齐拉西酮组与喹硫平组,各50例,分别给予齐拉西酮和喹硫平治疗8周,采用阳性症状与阴性症状量表(PANSS)和不良反应症状量表(TESS)评定疗效及不良反应。结果治疗8周后,齐拉西酮组与喹硫平组显效率为84.00%、80.00%,总有效率96.00%、94.00%,疗效差异无统计学意义(P>0.05)。齐拉西酮组与喹硫平组的不良反应发生率为18.00%、20.00%,差异无统计学意义(P>0.05)。结论齐拉西酮与喹硫平对早期精神分裂症的疗效相当,不良反应相当。Objective To compare the curative effects and adverse reactions of ziprasidone and quetiapine in the treatment of early schizophrenia.Methods A total of 100 schizophrenia patients were randomly divided into ziprasidone group and quetiapine group, with 50 cases in each group. They received ziprasidone and quetiapine respectively for the 8-week treatment. Positive and negative syndrome scale （PANSS） and treatment emergent symptom scale （TESS） were applied to evaluate curative effects and adverse reactions.Results After the treatment for 8 weeks, the excellent effect rates in the ziprasidone group and quetiapine group were respectively 84.00% and 80.00%. Their total effective rates were respectively 96.00% and 94.00%. The difference of curative effects was not statistically significant （P〉0.05）. The incidences of adverse reactions in the ziprasidone group and quetiapine group were respectively 18.00% and 20.00%, and the difference had no statistical significance （P〉0.05）. Conclusion Ziprasidone has the similar curative effect and adverse reactions as quetiapine in the treatment of early schizophrenia.

关 键 词：齐拉西酮 喹硫平 早期精神分裂症 

分 类 号：R749.3[医药卫生—神经病学与精神病学]